Treatment with ATRA plus arsenic trioxide (ATO), which degrades the PML/RARα fusion protein, results in the differentiation of APL cells and is the only highly effective molecular targeted strategy for AML [24]. The gene discussed is RARA; the disease is acute promyelocytic leukemia.